BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19730873)

  • 1. Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system.
    Tang CH; Pwu RF; Tsai IC; Wang HI; You SL; Chen CA; Scuffham PA; Hsieh CY; Chou CY; Lin SR; Chen YD; Chen CJ
    Arch Gynecol Obstet; 2010 Apr; 281(4):683-95. PubMed ID: 19730873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
    Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
    Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and costs of cervical intraepithelial neoplasia in the Korean population.
    Chang HK; Seo SS; Myong JP; Yu YL; Byun SW
    J Gynecol Oncol; 2019 May; 30(3):e37. PubMed ID: 30887758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of cervical intra-epithelial neoplasia (CIN): extensiveness and costs in The Netherlands.
    van Ballegooijen M; Koopmanschap MA; Habbema JD
    Eur J Cancer; 1995 Sep; 31A(10):1672-6. PubMed ID: 7488423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
    Mizukami A; Kaise T; Van Kriekinge G
    Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of abnormal cytology test results and costs associated with the prevention of cervical cancer in Spain.
    Blade A; Cararach M; Castro M; Catalá-López F; Pérez-Escolano I; de Sanjosé S
    J Low Genit Tract Dis; 2010 Oct; 14(4):311-8. PubMed ID: 20885158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage-specific treatment costs for cervical cancer in the United Kingdom.
    Wolstenholme JL; Whynes DK
    Eur J Cancer; 1998 Nov; 34(12):1889-93. PubMed ID: 10023311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population.
    Thorsteinsson K; Ladelund S; Jensen-Fangel S; Katzenstein TL; Johansen IS; Pedersen G; Junge J; Helleberg M; Storgaard M; Obel N; Lebech AM
    HIV Med; 2016 Jan; 17(1):7-17. PubMed ID: 26058995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.
    Giorgi Rossi P; Ricciardi A; Cohet C; Palazzo F; Furnari G; Valle S; Largeron N; Federici A
    BMC Public Health; 2009 Feb; 9():71. PubMed ID: 19243586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term financial costs of abnormal Pap smears to women and government in Australia.
    Kavanagh AM; Butler JR
    Aust N Z J Public Health; 1998; 22(3 Suppl):347-52. PubMed ID: 9629821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
    Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
    Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
    Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
    J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care.
    Subramanian S; Trogdon J; Ekwueme DU; Gardner JG; Whitmire JT; Rao C
    Womens Health Issues; 2010; 20(6):400-5. PubMed ID: 21050999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain.
    Castellsagué X; Rémy V; Puig-Tintoré LM; de la Cuesta RS; Gonzalez-Rojas N; Cohet C
    J Low Genit Tract Dis; 2009 Jan; 13(1):38-45. PubMed ID: 19098605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
    Tjalma WA; Fiander A; Reich O; Powell N; Nowakowski AM; Kirschner B; Koiss R; O'Leary J; Joura EA; Rosenlund M; Colau B; Schledermann D; Kukk K; Damaskou V; Repanti M; Vladareanu R; Kolomiets L; Savicheva A; Shipitsyna E; Ordi J; Molijn A; Quint W; Raillard A; Rosillon D; De Souza SC; Jenkins D; Holl K;
    Int J Cancer; 2013 Feb; 132(4):854-67. PubMed ID: 22752992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression.
    Liu P; Iden M; Fye S; Huang YW; Hopp E; Chu C; Lu Y; Rader JS
    Cancer Epidemiol Biomarkers Prev; 2017 Apr; 26(4):642-650. PubMed ID: 28069683
    [No Abstract]   [Full Text] [Related]  

  • 20. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine.
    Hooi DJ; Lissenberg-Witte BI; de Koning MNC; Pinedo HM; Kenter GG; Meijer CJ; Quint WG
    Sex Transm Infect; 2018 Jun; 94(4):263-267. PubMed ID: 29021405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.